Last Updated: May 24, 2026

Patent: 11,365,241

✉ Email this page to a colleague

Summary for Patent: 11,365,241

Title:	High concentration anti-C5 antibody formulations
Abstract:	The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), using the solutions. Also featured were therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment.
Inventor(s):	Ortiz Stephan, Gentile Jillian, Philominathan Leena, Routhier Eric, Mason Bruce
Assignee:	Alexion Pharmaceuticals, Inc.
Application Number:	US16633930
Patent Claims:	see list of patent claims

Details for Patent 11,365,241

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	ULTOMIRIS	ravulizumab-cwvz	Injection	761108	December 21, 2018	⤷ Start Trial	2038-07-27
Alexion Pharmaceuticals, Inc.	ULTOMIRIS	ravulizumab-cwvz	Injection	761108	October 09, 2020	⤷ Start Trial	2038-07-27
Alexion Pharmaceuticals, Inc.	ULTOMIRIS	ravulizumab-cwvz	Injection	761108	June 22, 2022	⤷ Start Trial	2038-07-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,365,241

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2019023564	⤷ Start Trial
United States of America	2025154233	⤷ Start Trial
United States of America	2023257456	⤷ Start Trial
United States of America	2023106734	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.